sales peaking in 2013 as oral drugs begin to take market share followed by two generic competitor launches, most likely Mylan and Momenta. Our base-case forecast results in Copaxone revenue below $1.0 billion by 2017. We think a handful of
marks for shareholder stewardship. Historically, Actavis has avoided an aggressive acquisition strategy like Teva and Mylan , but management has proved adept at finding niche generic opportunities, including Lipitor, Lovenox, and Concerta
NEW DELHI, Nov 26 (Reuters) - Biocon Ltd said on Tuesday it has won the Indian drug regulator's approval for marketing a generic version of Roche's Herceptin breast cancer treatment.
Note: Reuters has not verified this story and does not vouch for its accuracy.
Price target is now $50 (from $43). Meanwhile, the rumor mill is alive with talk of a possible merger with either Mylan ( MYL +0.8% ) or Valeant ( VRX +0.1% ). "People are looking for the company to do something,” an S&P analyst
Compared with its peers, Mylan 's less diversified operations increase ..... volatility in generic drug markets. Mylan faces considerable competition from ..... specialty drug segment. We estimate Mylan 's cost of capital at 9.5%.
Mylan ( MYL +0.2% ) prices $2B in bonds: $500M in 1.35% notes due 2016, $500M in 2.55% notes due 2019, $500M in 4.20% senior
Nov 18 (Reuters) - Mylan Inc : * Launches first generic Focalin XR capsules, 30 mg * Says awarded 180 days marketing exclusivity * Says dexmethylphenidate hydrochloride extended-release capsules,...
operating in biotechnology. The remaining 23% of assets are invested in small- and mid-cap pharmaceutical firms such as Mylan MYL , Salix SLXP, and Theravance THRX; the U.S.' largest pharmaceutical firms trade on the New York Stock Exchange
Mylan ( MYL ) Q3 2013 Earnings Call October 31, 2013 10:00 am ET Executives Kris ..... br/><a href='http://seekingalpha.com/article/1794142- mylan -management-discusses-q3-2013-results-earnings-call-transcript